SCHEMBL5578720

SCHEMBL5578720

Cc1ccc2c(c1)C1(CCN(C(=O)OC(C)(C)C)CC1)C(=O)N2Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.50
OPRD1 P41143 1/20 0.50
TP53 P04637 5/20 0.46
MAPT P10636 2/20 0.46
TACR1 P25103 1/20 0.44
C5AR1 P21730 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
OPRL1 P41146 2/20 0.43
OPRM1 P35372 1/20 0.43
LMNA P02545 2/20 0.42
ADAMTS5 Q9UNA0 2/20 0.42
EGLN1 Q9GZT9 1/20 0.42
CES1 P23141 1/20 0.42
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
USP30 Q70CQ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3737310 0.90 OPRK1 (0.49) OPRK1OPRD1TP53TACR1C5AR1
SCHEMBL3738796 0.89 OPRK1 (0.54) OPRK1OPRD1C5AR1HDAC1HDAC8
SCHEMBL3771547 0.89 OPRK1 (0.54) OPRK1OPRD1C5AR1HDAC1HDAC8
SCHEMBL14297231 0.87 OPRK1 (0.49) OPRK1OPRD1TP53MAPTTACR1
SCHEMBL5578543 0.86 OPRD1 (0.49) OPRK1OPRD1TP53MAPTTACR1
SCHEMBL13480003 0.81 OPRM1 (0.52) OPRK1OPRD1TP53TACR1OPRL1
SCHEMBL13479986 0.81 OPRL1 (0.60) OPRK1OPRD1MAPTHDAC1HDAC8
SCHEMBL21753390 0.79 HDAC1 (0.48) OPRK1OPRD1C5AR1HDAC1HDAC8
SCHEMBL10253956 0.78 OPRL1 (0.48) OPRK1OPRD1HDAC1HDAC8HDAC6
SCHEMBL3735215 0.78 OPRL1 (0.48) OPRK1OPRD1C5AR1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed
EP-1716148-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF Arena Pharmaceuticals, Inc. (US) 2006-11-02 EP disclosed
WO-2005063745-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL OPRK1 131/4885OPRD1 155/4885TP53 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.